Skip to main content

CORRECTION article

Front. Oncol., 05 March 2021
Sec. Women's Cancer
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.661128

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

This article is a correction to:

  1. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

    1. Read original article
\nQitong Chen&#x;Qitong Chen1†Dengjie Ouyang,&#x;Dengjie Ouyang1,2†Munawar AnwarMunawar Anwar1Ning XieNing Xie3Shouman WangShouman Wang4Peizhi FanPeizhi Fan5Liyuan QianLiyuan Qian6Gannong ChenGannong Chen1Enxiang ZhouEnxiang Zhou1Lei GuoLei Guo4Xiaowen GuXiaowen Gu5Boni DingBoni Ding6Xiaohong YangXiaohong Yang7Liping LiuLiping Liu7Chao DengChao Deng8Zhi XiaoZhi Xiao3Jing LiJing Li9Yunqi WangYunqi Wang10Shan ZengShan Zeng11Jinhui HuJinhui Hu12Wei ZhouWei Zhou13Bo QiuBo Qiu14Zhongming WangZhongming Wang15Jie WengJie Weng16Mingwen LiuMingwen Liu17Yi LiYi Li18Tiegang TangTiegang Tang19Jianguo WangJianguo Wang20Hui ZhangHui Zhang21Bin DaiBin Dai22Wuping TangWuping Tang23Tao WuTao Wu24Maoliang XiaoMaoliang Xiao25Xiantao LiXiantao Li26Hailong LiuHailong Liu27Lai LiLai Li28Wenjun Yi Wenjun Yi1*Quchang Ouyang Quchang Ouyang3*
  • 1Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
  • 2Department of General Surgery, Xiangya Hospital Central South University, Changsha, China
  • 3Department of Breast Internal Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
  • 4Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China
  • 5Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China
  • 6Department of Breast and Thyroid Surgery, Central South University Third Xiangya Hospital, Changsha, China
  • 7Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Cental South University, Changsha, China
  • 8Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
  • 9Department of Breast Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Cental South University, Changsha, China
  • 10Department of Traditional Chinese Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Cental South University, Changsha, China
  • 11Department of Internal Medicine – Oncology, Xiangya Hospital Central South University, Changsha, China
  • 12Department of Breast Surgery, The First Hospital Hunan University of Chinese Medicine, Changsha, China
  • 13Department of Breast and Thyroid Surgery, The Affiliated ZhuZhou Hospital of Xiangya School of Medicine Central South University, Zhuzhou, China
  • 14Department of Oncology, The Affiliated ZhuZhou Hospital of Xiangya School of Medicine Central South University, Zhuzhou, China
  • 15Department of Breast Surgery, The Third People's Hospital of Yongzhou, Yongzhou, China
  • 16Department of Oncology, The First People's Hospital of Yueyang, Yueyang, China
  • 17Department of Breast and Thyroid Surgery, The First People's Hospital of Xiangtan City, Xiangtan, China
  • 18Department of Oncology, The Third People's Hospital of Changde, Changde, China
  • 19Department of Oncology, Xiangtan Central Hospital, Xiangtan, China
  • 20Department of General Surgery, Xiangtan Central Hospital, Xiangtan, China
  • 21Department of Oncology, Central Hospital of Shaoyang, Shaoyang, China
  • 22Department of Breast and Thyroid Surgery, Central Hospital of Shaoyang, Shaoyang, China
  • 23Department of Breast Surgery, Shaoyang Hospital of Traditional Chinese Medicine, Shaoyang, China
  • 24Department of Oncology, The First People's Hospital of Changde, Changde, China
  • 25Department of Oncology, The Third Hospital of Hunan University of Chinese Medicine, Zhuzhou, China
  • 26Department of Oncology, The Central Hospital of Yiyang, Yiyang, China
  • 27Department of Internal Medicine – Oncology, The First People's Hospital of Chenzhou, Chenzhou, China
  • 28Department of Breast and Thyroid Surgery, The People's Hospital of Xiangtan County, Xiangtan, China

A Corrigendum on
Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

by Chen, Q., Ouyang, D., Anwar, M., Xie, N., Wang, S., Fan, P., et al. (2020). Front. Oncol. 10:811. doi: 10.3389/fonc.2020.00811

In the original article, there was an error. The following line was incorrect: “Second-line treatment was that given to a patient with recurrence within 12 months of discontinuation of trastuzumab, or recurrence during adjuvant therapy with trastuzumab.”

A correction has been made to Patients and Methods, Data Collection, paragraph 2:

“Second-line treatment was that given to a patient with recurrence within 12 months of discontinuation of trastuzumab, or recurrence during adjuvant therapy with trastuzumab, or progression following first-line treatment.”

In the original article, the second subtitle of the Results section was also incorrect: “Effeteness of Switching Use of TKIs”

The correct version of this subtitle is as follows: “Effectiveness of Switching Use of TKIs”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: breast cancer, HER2, pyrotinib, tumor mutation burden, metastases

Citation: Chen Q, Ouyang D, Anwar M, Xie N, Wang S, Fan P, Qian L, Chen G, Zhou E, Guo L, Gu X, Ding B, Yang X, Liu L, Deng C, Xiao Z, Li J, Wang Y, Zeng S, Hu J, Zhou W, Qiu B, Wang Z, Weng J, Liu M, Li Y, Tang T, Wang J, Zhang H, Dai B, Tang W, Wu T, Xiao M, Li X, Liu H, Li L, Yi W and Ouyang Q (2021) Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis. Front. Oncol. 11:661128. doi: 10.3389/fonc.2021.661128

Received: 30 January 2021; Accepted: 16 February 2021;
Published: 05 March 2021.

Edited and reviewed by: Masakazu Toi, Kyoto University, Japan

Copyright © 2021 Chen, Ouyang, Anwar, Xie, Wang, Fan, Qian, Chen, Zhou, Guo, Gu, Ding, Yang, Liu, Deng, Xiao, Li, Wang, Zeng, Hu, Zhou, Qiu, Wang, Weng, Liu, Li, Tang, Wang, Zhang, Dai, Tang, Wu, Xiao, Li, Liu, Li, Yi and Ouyang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wenjun Yi, yiwenjun@csu.edu.cn; Quchang Ouyang, oyqc1969@126.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.